Access Issues Loom Large at Munich Workshop on Biologics and Biosimilars
When should patients switch from one medicine to another for non-medical reasons? How can pharmacovigilance processes successfully monitor patients’ reactions to a medicine? And, perhaps most importantly, how do we ensure that patients are informed participants in decisions about their medication?
How Balanced Treatment, Innovation & Better Policy Can Help Solve the Opioid Epidemic
“Doctor, make my pain go away.” I hear this plea, in one form or another, from patients on a daily basis. Yet it presents physicians like me with a troubling conundrum.
Clinical Trials Awareness Week Focuses on Policy, Participation
What can the federal government do to raise clinical trials awareness? Maybe a lot, suggests one organization.
Health Plan Report Cards Reveal High Rejection Rate for Cholesterol Meds
Rejection is never pleasant. But for the 34,459 patients whose health plans refuse to cover advanced treatment for high cholesterol, it could also be deadly.
Tubing Mix-ups Pose New Dangers for Infants
Robin Rogers was 35 weeks pregnant when she began to suffer from significant vomiting and dehydration. She was admitted to the hospital near her home in Kansas. To correct her fluid and nutrition levels, Robin had two tubes placed: one, a feeding tube; the other a PICC line, often used to draw blood or deliver antibiotics.
Keeping Asthma Medication within Patients’ Reach
A new bureaucratic obstacle could make it even harder for asthma patients to get the medicine they need.
Trials Data Raises Hopes in Cystic Fibrosis Community
Promising clinical trials data has excited patients with cystic fibrosis and their families. But will access barriers dash their hopes for more and better treatment options?
IfPA Offers the Physician’s Perspective on Oncology Value Models
What is good value in terms of cancer treatment? The question, amid rising cancer care costs, has prompted a surge of oncology value models in recent years.
Summit on Biologics and Biosimilars Tackles Choice, Switching & Patient Access
Physicians and patients are no longer asking if a biological medicine is the best choice, but – more likely – which biological medicine is the best choice. This opening thought from Alliance for Patient Access Chairman David Charles, MD, set the tone for the organization’s second annual National Policy and Advocacy Summit on Biologics and Biosimilars, held Thursday in Washington, DC.
New AfPA Video Examines “The Interchangeability Promise”
First came biologics, then biosimilars. And soon, explains a newly released video from The Alliance for Patient Access, patients can expect interchangeable biosimilars.
